David L Stern

US Patent:

6391300, May 21, 2002

Filed:

Nov 16, 1998

Appl. No.:

09/192905

Inventors:

Eric Rose - Tenafly NJ
David Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Talia Spanier - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3836

US Classification:

4241451, 424 9464, 4241581, 435226, 514 2, 514 12, 530381

Abstract:

This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0. 1 g/ml plasma to about 250 g/ml plasma or from about 0. 5 g/ml plasma to about 25 g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient.

US Patent:

6398947, Jun 4, 2002

Filed:

Sep 27, 1999

Appl. No.:

09/406440

Inventors:

Jeffrey S. Beck - Burlington NJ
Vinaya A. Kapoor - Kirkwood Voorhees NJ
David L. Stern - Mount Laurel NJ
John H. Thurtell - Glen Mills PA

Assignee:

Exxon Mobil Oil Corporation - Fairfax VA

International Classification:

C10G 3506

US Classification:

208 65, 208 63, 208 66, 208134, 208137, 208138

Abstract:

The patent application discloses an integrated process for reformate upgrading. Such a process enables production of a high value product slate, by incorporating the step of reforming along with reaction/diffusion with a zeolite.

US Patent:

6504075, Jan 7, 2003

Filed:

Jan 22, 2001

Appl. No.:

09/767183

Inventors:

Jeffrey S. Beck - Burlington NJ
Carrie L. Kennedy - Turnersville NJ
Wieslaw J. Roth - Sewell NJ
David L. Stern - Mount Laurel NJ

Assignee:

ExxonMobil Oil Corporation - Fairfax VA

International Classification:

C07C 552

US Classification:

585475, 585481

Abstract:

A synthetic porous crystalline material has the structure of ZSM-5 and a composition involving the molar relationship: wherein X is a trivalent element; Y is a tetravalent element; and n is less than 25, and wherein the slope of the nitrogen sorption isotherm of the material at a partial pressure of nitrogen of 0. 4 to 0. 7 and a temperature 77Â K is greater than 30. The material has a mesoporous surface area (MSA) greater than 45 m /g and is useful as a catalyst in the liquid phase isomerization of xylene.

US Patent:

6555651, Apr 29, 2003

Filed:

Oct 9, 1997

Appl. No.:

08/948131

Inventors:

David Stern - Great Neck NY
Shi Du Yan - New York NY
Ann Marie Schmidt - Franklin Lakes NJ
Ira Lamster - Wyckoff NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3800

US Classification:

530324, 530300

Abstract:

The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (SEQ. ID No: 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid- peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid- peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid- peptide with the receptor for advanced glycation endproduct.

US Patent:

6563015, May 13, 2003

Filed:

Aug 14, 2000

Appl. No.:

09/638649

Inventors:

David M. Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Shi Du Yan - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3300

US Classification:

800 3, 800 12, 800 18

Abstract:

The invention provides for a non-human transgenic animal whose cells contain a recombinant DNA sequence comprising: (a) a nerve tissue specific promoter operatively linked to a DNA sequence which encodes human receptor for advanced glycation endproducts (RAGE), and (b) a nerve tissue specific promoter operatively linked to a DNA sequence encoding a mutant human amyloid precursor protein hAPP695, hAPP751 and hAPP770 bearing mutations linked to familial Alzheimers disease in humans, wherein said non-human transgenic animal exhibits at least one phenotype from the group consisting of: increased expression of M-CSF gene in cerebral cortex; increased expression of IL-6 gene in cerebral cortex; increased neuronal stress; increased neurotoxicity; neuron loss; increased level of activated form of caspase 3 in brain; and increased level of phosphorylated tau protein in brain.

US Patent:

6576582, Jun 10, 2003

Filed:

Nov 15, 1995

Appl. No.:

08/558309

Inventors:

Jeffrey S. Beck - Lawrenceville NJ
Jane C. Cheng - Clarksburg NJ
Sharon B. McCullen - Newtown PA
David H. Olson - Pennington NJ
David L. Stern - Lawrenceville NJ

Assignee:

ExxonMobil Oil Corporation - Fairfax VA

International Classification:

B01J 2906

US Classification:

502 71, 502 63, 502 64, 502 77, 502 85

Abstract:

There is provided a substantially binder-free catalytic molecular sieve which has been modified by being ex situ selectivated with a silicon compound. The ex situ selectivation involves exposing the molecular sieve to at least two silicon impregnation sequences, each sequence comprising an impregnation with a silicon compound followed by calcination. The catalyst may be used in a hydrocarbon conversion process, such as toluene disproportionation.

US Patent:

6610264, Aug 26, 2003

Filed:

May 5, 1995

Appl. No.:

08/435920

Inventors:

John Scott Buchanan - Trenton NJ
David L. Stern - Lawrenceville NJ
Gerald J. Teitman - Vienna VA

Assignee:

ExxonMobil Oil Corporation - Fairfax VA

International Classification:

B01D 5348

US Classification:

4232421, 423222, 42324401, 42324402, 42324406, 42324407, 4235731, 4235741, 4235768

Abstract:

A process and system is disclosed for removing sulfur from tail-gas emitted from a Claus sulfur recovery process. First, the tail-gas is oxidized so as to convert sulfur therein to sulfur oxides. Oxidized tail-gas is directed into an absorber where a solid absorbent absorbs substantially all the sulfur oxides thereon. After allowing sufficient time for a desired amount of sulfur oxides to be absorbed, absorption is ceased. Next, the solid absorbent containing the absorbed sulfur oxides is contacted with a reducing gas so as to release an off gas containing hydrogen sulfide and sulfur dioxide. Upon releasing sulfur from the solid absorbent, the solid absorbent is regenerated and redirected into the absorber. Sulfur in the off gas emitted by regeneration is concentrated to an extent sufficient for use within a Claus sulfur recovery process for conversion to elemental sulfur. By combining this process with a Claus sulfur recovery process, sulfur dioxide emissions can be reduced to less than about two parts per million.

US Patent:

6660896, Dec 9, 2003

Filed:

Apr 16, 2003

Appl. No.:

10/418439

Inventors:

John Scott Buchanan - Lambertville NJ
Xiaobing Feng - Houston TX
Gary David Mohr - Houston TX
David L. Stern - Annandale NJ

Assignee:

ExxonMobil Chemical Patents Inc. - Houston TX

International Classification:

C07C 527

US Classification:

585481, 585480, 585482, 585314

Abstract:

In a process for isomerizing a feed comprising ethylbenzene and a mixture of xylene isomers, the feed is first contacted under xylene isomerization conditions with a first catalyst composition to produce an intermediate product having a higher para-xylene concentration than the feed, and then the intermediate product is contacted under ethylbenzene isomerization conditions with a second catalyst composition. The second catalyst composition comprises a hydrogenation-dehydrogenation component and a molecular sieve having 10-membered ring pores and is effective to selectively isomerize at least part of the ethylbenzene in the intermediate product to para-xylene and thereby produce a further product having a para-xylene concentration greater than the equilibrium concentration of para-xylene at said ethylbenzene isomerization conditions.